ArticleHead and neck pathology2026
Molecularly Variant Synovial Sarcoma of the Lower Lip: MN1::SSX1 Fusion as a Diagnostic Pitfall in the Head and Neck.
Article in Head and neck pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial sarcoma is a malignant mesenchymal neoplasm typically characterized by SS18::SSX gene fusions. Although most commonly arising in the extremities, it rarely occurs in the head and neck region. We report a case of monophasic synovial sarcoma of the lower lip harboring a rare MN1::SSX1 fusion that presented a diagnostic challenge due to negative standard molecular testing. A 23-year-old woman presented with a slowly enlarging right lower lip mass. Imaging revealed a well-defined subcutaneous lesion without mandibular invasion and mildly prominent bilateral cervical lymph nodes. Core biopsy demonstrated a cellular spindle cell neoplasm with uniform cells arranged in intersecting fascicles. Immunohistochemistry showed diffuse nuclear SSX and TLE1 expression with focal cytokeratin positivity. The SS18-SSX fusion-specific antibody was negative, and fluorescence in situ hybridization showed no SS18 rearrangement. Given the morphologic and immunophenotypic features suggestive of synovial sarcoma, next-generation sequencing was performed and identified an MN1::SSX1 fusion. The patient underwent complete surgical excision with negative margins. She didn’t receive additional therapy, and no recurrence or metastasis has been identified at 16 months follow-up. This case represents the second reported synovial sarcoma with MN1::SSX1 fusion and highlights an important diagnostic pitfall: rare variant fusions may yield negative SS18-based immunohistochemistry and molecular assays despite classic morphologic features. This case emphasizes the importance of comprehensive molecular testing when clinical suspicion for synovial sarcoma remains high despite negative standard SS18-targeted assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.